Forescout Addresses Modern SecOps Challenges with Launch of Forescout XDR
1.3.2023 18:00:00 EET | Business Wire | Press release
Forescout Technologies Inc., the global leader in automated cybersecurity, today unveiled Forescout XDR, to help enterprises better detect, investigate, and respond to the broadest range of advanced threats, across the extended enterprise.
A typical SOC is flooded with 450 alerts per hour1, and analysts waste precious time trying to correlate low fidelity alerts and chasing false positives, often at the expense of focusing on legitimate attacks. Until now, a security operations center’s (SOC) field of view for threat detection and response has excluded critical devices that are increasingly common points of attack, including operational technology (OT), industrial control systems (ICS), building management systems (BMS), and medical and IoT devices. In addition, the technology stack that SecOps teams have had to rely on has made it difficult to respond to these threats in a rapid and comprehensive manner.
“The true value of an XDR solution lies in its ability to ingest telemetry and data from across the entire enterprise: cloud, campus, remote and datacenter environments, and every managed and unmanaged connected device. This is what the X in XDR is all about, after all,” said Justin Foster, CTO, Forescout. “Traditional XDR products lack this capability, or they only leverage data from the vendor’s own EDR or a few other security tools. This significantly limits the flexibility, scalability and effectiveness that an XDR solution must provide.”
Through the advanced application of data science and automation, Forescout XDR generates one high-fidelity alert that truly warrants analyst investigation, from every 50 million logs ingested, per hour2. Because Forescout XDR is vendor- and EDR-agnostic, this ingestion includes data from over 170 security, infrastructure, application, cloud/SaaS and enrichment sources, and dozens of leading vendors. And with over 70 sources of threat intelligence and 1500 verified detection rules and models, and data onboarding included, Forescout XDR customers can be operational within hours, actively detecting, investigating, and responding to threats.
“Forescout XDR, with the breadth and richness of its capabilities, particularly its dashboards and reporting, provides an out-of-the-box solution to SOC challenges that we spent 18-24 months trying to address,” said Samer Mansour, CISO, Panasonic Corporation of North America. “It was easy to deploy, and fully operational in a matter of weeks. And with its tight integration to Forescout’s network security and visibility solutions, and our broader security tech stack, it gives us the ability to exert a lot more control across our IT and OT environments, and further elevate our overall security.”
Seamless integration with Forescout’s industry-leading network access control solution helps ensure that customers can:
- Reduce the attack surface, and the risk of an attack in the first place, by preventing compromised or non-compliant devices from connecting to their networks. This proactive approach to XDR further elevates the effectiveness and performance of a modern SOC.
- Automate response workflows that can immediately touch every managed and unmanaged connected device, across the enterprise. This reduces an attack's blast radius in real-time, allowing proper mitigation or remediation measures to be completed.
Because Forescout XDR has a multi-tenant architecture and supports local data storage while also being able to provide an aggregated global view of threats and SOC performance, it is ideally suited to large enterprises, multi-nationals, organizations with regional SOCs and managed security service providers (MSSPs).
Pricing
SaaS licensing is based on the total number of endpoints in the enterprise. As such, customers have the flexibility to leverage the data sources needed to fully support the use cases important to them, and help ensure better detection, without concern for escalating or fluctuating costs associated with cloud log storage.
About Forescout
Forescout Technologies, Inc. delivers automated cybersecurity across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types- IT, IoT, OT, IoMT, and cloud environments. The Forescout Platform provides complete asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets. www.forescout.com
Managing cyber risk, together.
|
1 |
“The 2020 State of Security Operations,” Forrester Consulting |
|
|
2 |
Based on aggregate Forescout data from a 1-year period (Dec 2021-2022), across 30 enterprise customers, representing a range of company sizes and industries. |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005455/en/
Contact information
Media Contact:
Emily Alfano
Manager of PR
Emily.alfano@forescout.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
